



203153

00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

| Pat Pat Phy | ient Name: ient ID: ient Group No: /sician Office Address: | - | _ Date: _ Patient Date Of Birth: Patient Phone: | Phys Spec | 9/9/2024 Physician Name: Specialty: Physician Office Telephone: | | | |
|-------------------------------------|---|---|--|--------------|--|---|--|--|
| Drug Name (specify drug) Quantity: | | Frequency: | | | | | | |
| | | | Expected Length of Therapy: ICD Code: | | | | | |
| Cor | | | | | | | | |
| Plea | What is the diagnosis? | e answer for each applications ancer (NSCLC) (If checked, | • | | | | | |
| | Other, please specify. | (If checked, no further ques | stions) | | | | | |
| 2. | Is the patient currently re | eceiving treatment with the r | equested medication? | Y | | N | | |
| 3. | Is there evidence of diseregimen? | ease progression or unaccep | otable toxicity while on the current | Y | | N | | |
| 4. | Which of the following do notes or test results of m amplification, where app | nesenchymal-epithelial trans | TION REQUIRED: Please attach char ition (MET) exon 14 status or (MET) | rt | | | | |
| | Mesenchymal-epitheli go to 5) | al transition (MET) exon 14 | skipping positive tumor (If checked, | | | | | |
| | High-level mesenchyr questions) | mal-epithelial transition (MET | Γ) amplification (If checked, no furthe | r | | | | |
| | None of the above (If | checked, no further question | ns) | | | | | |
| | Unknown (If checked, | no further questions) | | | | | | |
| | ACTION REQUIRED: | Submit supporting documer | ntation | | | | | |
| 5. | | ng in which the requested me | edication will be used? | | _ | | | |
| | Advanced disease (If checked, go to 6) | | | | Ш | | | |
| | Metastatic disease (including brain metastases from NSCLC) (If checked, go to 6) | | | | | | | |
| | Recurrent disease (If checked, go to 6) | | | | | | | |
| | Other, please specify. | (If checked, no further ques | stions) | | | | | |
| 6. | Will the requested medic | cation be used as a single a | gent? | Y | | N | | |
| 7. | Has the patient experier mutation-targeted regim | nced disease progression on en? | therapy with a MET exon 14 skippin | g Y | | N | | |

Γ

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.